Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .
Usefulness of HMG-CoA Reductase Inhibitor in Japanese Hyperlipidemic Women within Seven Years of Menopause
Objective : To assess the therapeutic value of treatment with an HMG-CoA reductase inhibitor in women with hypoestrogenic hyperlipidemia caused by menopause . Design : Fifty-six women with total cholesterol ( TC ) levels of 220 mg/dl or more who were within 7 years of menopause were r and omly assigned to receive an HMG-CoA reductase inhibitor ( pravastatin 10 mg/day ; treated group , 26 patients ) or no medical treatment ( nontreated group , 30 patients ) in this 6-month nonblinded prospect i ve trial . Results : In the treated group , the mean ( SD ) TC levels decreased significantly from 254.5 ± 22.3 mg/dl at baseline to 204.7 ± 22.2 mg/dl ( 19.6 % ) , and the mean low-density lipoprotein cholesterol ( LDL-C ) level decreased significantly from 146.7 ± 30.5 to 104.3 ± 22.5 mg/dl ( 28.9 % ) ; the mean arteriosclerotic index decreased significantly from 2.98 to 2.08 ( 30.2 % ) . There were no significant changes in either triglyceride levels or high-density lipoprotein cholesterol ( HDL-C ) levels . In the nontreated group , there were no significant changes in the TC , HDL-C , LDL-C , or triglyceride levels ; there was also no change in the arteriosclerotic index . After 6 months , the TC level , LDL-C level , and arteriosclerotic index were significantly lower in the treated group compared with the nontreated group ( p < 0.01 ) . Conclusions : The results indicate that the HMG-CoA reductase inhibitor lowered TC and LDL-C levels and was useful in the treatment of hypoestrogenic hyperlipidemia for periods of at least 6 months
Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .